<DOC>
	<DOC>NCT02885857</DOC>
	<brief_summary>Safety and efficacy of long-term application of Shenyankangfu Tablets in Large sample of patients with chronic kidney disease.</brief_summary>
	<brief_title>Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease</brief_title>
	<detailed_description>Research purpose: Safety and efficacy of long-term application of Shenyankangfu Tablets in Large sample of patients with chronic kidney disease. The crowd: patients with primary glomerular nephritis, diabetic nephropathy patients. Study design: a multicenter clinical study design, openness. The study drug: Shenyan Kangfu Tablets. Statistical analysis: Research plan is determined, by statistical professionals responsible for negotiation with the principal investigator for statistical analysis plan.</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>1. Diagnosed with primary glomerulonephritis or diabetic nephropathy; 2. Aged from 18 to 70 years，male or female 3. GFR≥45ml/min/1.73㎡ 4. 0.5g≤24 hours proteinuria≤3.0g 5. glycated hemoglobin (HbAlc) ≤8% (This has been limited to patients with diabetic nephropathy) 6. Traditional Chinese medicine syndrome conform QiYin Deficiency 7. Obtain the agreement of patients or their guardians, and signed informed consent file 1. Secondary nephropathy 2. People allergic to Shenyankangfu tables 3. Combined with severe primary disease of heart, brain, liver and hematopoietic system, or other serious diseases can affect patient's life 4. Pregnant or lactating women 5. Be participating in another clinical study at the same period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>